Corvus Pharmaceuticals Inc sell nvestor
Start price
18.09.21
/
50%
€5.20
Target price
18.09.22
€2.00
Performance (%)
-22.69%
End price
02.10.21
€4.02
Summary
This prediction ended on 02.10.21 with a price of €4.02. The prediction for Corvus Pharmaceuticals Inc closed with a convincing performance of -22.69%. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Corvus Pharmaceuticals Inc | -9.510% | -9.510% | 18.252% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% |
According to nvestor what are the pros and cons of Corvus Pharmaceuticals Inc for the foreseeable future?
Pros
Cons
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
Below average Management
Bad culture
Probably not worthwhile Investment
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Few uniques
Dependend from some customers or products
Growths slower than the competition
Significant cyclical dependencies
Little innovation
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Little known brand
Business model of the past or high risk
Comments by nvestor for this prediction
In the thread Corvus Pharmaceuticals Inc diskutieren
In the thread Trading Corvus Pharmaceuticals Inc
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.